Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

BCAT1 defines gliomas by IDH status

Nature Medicine volume 19, pages 816–817 (2013)Cite this article

Subjects

Metabolic alterations, such as those caused by mutations in the enzyme isocitrate dehydrogenase (IDH), define a clinically distinct subset of primary brain cancers. Expression of BCAT1 is now reported as a new metabolic change defining brain cancers without IDH mutations (pages 901–908).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential fates for the BCAAs in gliomas.

Marina Corral

References

  1. Wise, D.R. & Thompson, C.B. Trends Biochem. Sci. 35, 427–433 (2010).

    Article  CAS  Google Scholar 

  2. Commisso, C. et al. Nature 497, 633–637 (2013).

    Article  CAS  Google Scholar 

  3. Kamphorst, J.J. et al. Proc. Natl. Acad. Sci. USA 110, 8882–8887 (2013).

    Article  CAS  Google Scholar 

  4. Tönjes, M. et al. Nat. Med. 19, 901–908 (2013).

    Article  Google Scholar 

  5. Hutson, S.M., Sweatt, A.J. & Lanoue, K.F. J. Nutr. 135, 1557S–1564S (2005).

    Article  CAS  Google Scholar 

  6. Baracos, V.E. & Mackenzie, M.L. J. Nutr. 136, 237S–242S (2006).

    Article  CAS  Google Scholar 

  7. Wen, P.Y. & Kesari, S. N. Engl. J. Med. 359, 492–507 (2008).

    Article  CAS  Google Scholar 

  8. Yan, H. et al. N. Engl. J. Med. 360, 765–773 (2009).

    Article  CAS  Google Scholar 

  9. Noushmehr, H. et al. Cancer Cell 17, 510–522 (2010).

    Article  CAS  Google Scholar 

  10. Parsons, D.W. et al. Science 321, 1807–1812 (2008).

    Article  CAS  Google Scholar 

  11. Rohle, D. et al. Science 340, 626–630 (2013).

    Article  CAS  Google Scholar 

  12. Losman, J.-A. & Kaelin, W.G. Genes Dev. 27, 836–852 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jared R. Mayers and Matthew G. Vander Heiden are at the Koch Institute for Integrative Cancer Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.,

    Jared R Mayers & Matthew G Vander Heiden

  2. Matthew G. Vander Heiden is also at the Dana-Farber Cancer Institute, Boston, Massachusetts, USA.,

    Matthew G Vander Heiden

Authors
  1. Jared R Mayers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew G Vander Heiden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew G Vander Heiden.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayers, J., Vander Heiden, M. BCAT1 defines gliomas by IDH status. Nat Med 19, 816–817 (2013). https://doi.org/10.1038/nm.3263

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3263

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer